Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.55 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29535576 | 1.00 | KDM4E (0.73) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5880414 | 1.00 | KDM4E (0.73) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2216260 | 0.85 | KDM4E (0.98) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL12765863 | 0.85 | KDM4E (0.98) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL19829391 | 0.85 | KDM4E (0.98) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL11881740 | 0.83 | KDM4E (0.73) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL19161142 | 0.81 | KDM4E (1.00) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1491317 | 0.81 | KDM4E (1.00) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1491505 | 0.81 | KDM4E (1.00) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1491315 | 0.81 | KDM4E (1.00) | KDM4ECYP1A2CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3600451-B1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2024-12-12 | — | — | US | disclosed |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2022-08-04 | — | — | US | disclosed |
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MINERVA BIOTECHNOLOGIES CORPORATION | 2021-09-30 | — | — | US | disclosed |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2021-03-25 | — | — | US | disclosed |
| EP-3600451-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | Minerva Biotechnologies Corporation (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018183654-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299109-A1 | AGENTS FOR TREATING CANCER AND METHODS FOR IDENTIFYING SAID AGENTS | MCL1, CD44, EPCAM | KDM4E 970/4885CYP1A2 4081/4885CYP2D6 4379/4885 |
| US-12202799-B2 | Agents for differentiating stem cells and treating cancer | MCL1, CD44, CRABP2 | KDM4E 2543/4885CYP1A2 4669/4885CYP2D6 4801/4885 |
| US-20210087143-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | KDM4E 2543/4885CYP1A2 4669/4885CYP2D6 4801/4885 |
| US-12630512-B2 | Agents for differentiating stem cells and treating cancer | MCL1, POU2F1, NES | KDM4E 1753/4885CYP1A2 2832/4885CYP2D6 3225/4885 |
| US-20240409515-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | KDM4E 2543/4885CYP1A2 4669/4885CYP2D6 4801/4885 |
| US-20220242823-A1 | AGENTS FOR DIFFERENTIATING STEM CELLS AND TREATING CANCER | MCL1, CD44, CRABP2 | KDM4E 2543/4885CYP1A2 4669/4885CYP2D6 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.